![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Estimating the HCV treatment reach in high-risk groups in order to meet 2030 WHO elimination targets
|
|
|
AASLD 2022 Nov 4-8
Stevens W1, Marx SE2, Jiao S2, Collins MA2, Kaur J2, Jeffries D.1
1. Medicus Economics, LLC, Boston, Massachusetts, USA
2. AbbVie Inc., North Chicago, Illinois, USA
![1107221](../images/110722/110722-10/1107221.gif)
![1107222](../images/110722/110722-10/1107222.gif)
![1107223](../images/110722/110722-10/1107223.gif)
![1107224](../images/110722/110722-10/1107224.gif)
![1107225](../images/110722/110722-10/1107225.gif)
![1107226](../images/110722/110722-10/1107226.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|